Conduit Pharmaceuticals Stock Buy Hold or Sell Recommendation
| CDT Stock | 2.55 0.21 7.61% |
Considering the 90-day investment horizon and your above-average risk tolerance, our recommendation regarding Conduit Pharmaceuticals is 'Strong Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Conduit Pharmaceuticals given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Conduit Pharmaceuticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Conduit Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Conduit Stock please use our How to Invest in Conduit Pharmaceuticals guide. Note, we conduct extensive research on individual companies such as Conduit and provide practical buy, sell, or hold advice based on investors' constraints. Conduit Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices.
Conduit |
Execute Conduit Pharmaceuticals Buy or Sell Advice
The Conduit recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Conduit Pharmaceuticals. Macroaxis does not own or have any residual interests in Conduit Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Conduit Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Conduit Pharmaceuticals Trading Alerts and Improvement Suggestions
| Conduit Pharmaceuticals generated a negative expected return over the last 90 days | |
| Conduit Pharmaceuticals has high historical volatility and very poor performance | |
| Conduit Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Conduit Pharmaceuticalshas 4,605,153 shares shorted by Conduit Pharmaceuticals investors is about 200% of outstending shares | |
| Reported Net Loss for the year was (535 K) with profit before taxes, overhead, and interest of 0. | |
| Conduit Pharmaceuticals generates negative cash flow from operations | |
| About 49.0% of the company shares are held by company insiders |
Conduit Pharmaceuticals Returns Distribution Density
The distribution of Conduit Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Conduit Pharmaceuticals' future price movements. The chart of the probability distribution of Conduit Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Conduit Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Conduit Pharmaceuticals returns is essential to provide solid investment advice for Conduit Pharmaceuticals.
| Mean Return | -1.49 | Value At Risk | -20.63 | Potential Upside | 17.39 | Standard Deviation | 12.62 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Conduit Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Conduit Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Conduit Pharmaceuticals or Life Sciences Tools & Services sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Conduit Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Conduit stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -1.67 | |
β | Beta against Dow Jones | 1.87 | |
σ | Overall volatility | 12.62 | |
Ir | Information ratio | -0.13 |
Conduit Pharmaceuticals Volatility Alert
Conduit Pharmaceuticals is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Conduit Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Conduit Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Conduit Pharmaceuticals Fundamentals Vs Peers
Comparing Conduit Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Conduit Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Conduit Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Conduit Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Conduit Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Conduit Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Conduit Pharmaceuticals to competition |
| Fundamentals | Conduit Pharmaceuticals | Peer Average |
| Return On Asset | -3.22 | -0.14 |
| Current Valuation | 6.44 M | 16.62 B |
| Shares Outstanding | 1.54 M | 571.82 M |
| Shares Owned By Insiders | 49.11 % | 10.09 % |
| Shares Owned By Institutions | 4.05 % | 39.21 % |
| Number Of Shares Shorted | 4.61 M | 4.71 M |
| EBITDA | (324 K) | 3.9 B |
| Net Income | (535 K) | 570.98 M |
| Total Debt | 985 K | 5.32 B |
| Book Value Per Share | (0.01) X | 1.93 K |
| Cash Flow From Operations | (7.72 M) | 971.22 M |
| Short Ratio | 0.14 X | 4.00 X |
| Earnings Per Share | (23.00) X | 3.12 X |
| Number Of Employees | 7 | 18.84 K |
| Beta | 2.12 | -0.15 |
| Market Capitalization | 3.92 M | 19.03 B |
| Total Asset | 7.22 M | 29.47 B |
| Retained Earnings | (11.3 M) | 9.33 B |
| Working Capital | 3.93 M | 1.48 B |
| Net Asset | 7.22 M |
Note: Acquisition by Fromm Charles of 15700 shares of Conduit Pharmaceuticals at 10.0 subject to Rule 16b-3 [view details]
Conduit Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Conduit . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Conduit Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Conduit Pharmaceuticals? Buying financial instruments such as Conduit Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Conduit Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Communication Services Thematic Idea Now
Communication Services
Companies that provide networking, telecom, and long distance services. The Communication Services theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Communication Services Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Conduit Stock Analysis
When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.